TABLE 2.

Clinical trial of tumor immunity associated with CD47 antibody

Start year	NCT ID	Cancer Types	Interventions	Individual & Combination	Format & IgG	Characteristics
2014	NCT02216409136	• Solid Tumor	Hu5F9‐G4	• Monotherapy	McAb & IgG4	Phase 1
2015	NCT02678338137	• Acute Myeloid Leukemia	Hu5F9‐G4	• Monotherapy	McAb & IgG4	Phase 1
2015	NCT02367196138	• Hematologic Neoplasms	CC−90002	• Monotherapy • Combine with Rituximab	McAb & IgG4	Phase 1
2016	NCT02953782139	• Colorectal Neoplasms • Solid Tumors	Hu5F9‐G4	•Monotherapy •Combine with Cetuximab	McAb & IgG4	Phase 1 Phase 2
2016	NCT02663518140	• Hematologic Malignancies • Solid Tumor	TTI−621	• Monotherapy • Combine with Rituximab • Combine with Nivolumab	CD47 infusion protein & IgG1	Phase 1
2016	NCT02641002141	• Leukemia, Myeloid, Acute	CC−90002	• Monotherapy	McAb & IgG4	Phase 1
2016	NCT02890368142	• Solid Tumors • Melanoma • Merkel‐cell Carcinoma • Squamous Cell Carcinoma • Breast Carcinoma • Human Papillomavirus‐Related Malignant Neoplasm • Soft Tissue Sarcoma	TTI−621	• Monotherapy • Combine with PD−1/PD‐L1 Inhibitor • Combine with PEGylated interferon−2a • Combine with T‐Vec • Combine with radiation	CD47 infusion protein & IgG1	Phase 1
2016	NCT02953509143	• Lymphoma, Non‐Hodgkin • Lymphoma, Large B Cell, Diffuse • Indolent Lymphoma	Hu5F9‐G4	• Monotherapy • Combine with Rituximab	McAb &IgG4	Phase 1 Phase 2
2016	NCT03530683144	• Lymphoma • Myeloma	TTI−622	• Monotherapy • Combine with Rituximab • Combine with Nivolumab • Combine with PD−1 Inhibitor • Combine with	CD47 infusion protein & IgG4	Phase 1

Start Year	NCT Number	Conditions	Interventions	Individual & Combination	Format & IgG	Characteristics
				Proteasome‐inhibitor Regimen
2017	NCT03248479145	• Acute Myeloid Leukemia	Hu5F9‐G4	• Monotherapy	McAb & IgG4	Phase 1
2018	NCT03717103146	• Advanced Malignancies	IBI188	• Monotherapy • Combine with Rituximab	McAb & IgG4	Phase 1
2018	NCT03512340147	• Advanced Solid Cancers • Hematologic Cancers	SRF231	• Monotherapy	Anti‐CD47 body & Unknown	Phase 1
2018	NCT03527147148	• Non‐Hodgkin's Lymphoma • Diffuse Large B Cell Lymphoma	Hu5F9‐G4	•Monotherapy	McAb & IgG4	Phase 1
2019	NCT03763149149	• Advanced Malignancies	IBI188	• Monotherapy	McAb & Ig G4	Phase 1
2019	NCT04097769150	• Advanced Solid Tumor	HX009	• Monotherapy	anti‐PD−1/CD47 infusion protein	Phase 1
2019	NCT03957096151	• Soft Tissue Sarcoma • Colorectal Cancer • Head and Neck Squamous Cell Carcinoma • Non‐small‐cell Lung Carcinoma • Breast Carcinoma • Ovarian Carcinoma • Exocrine Pancreatic Carcinoma • Gastric Carcinoma • Melanoma	SGN‐CD47 M	• Monotherapy	McAb& Unknown	Phase 1
2020	NCT04257617152	• Locally Advanced Solid Tumor	ZL1201	• Monotherapy	McAb & Unknown	Phase 1

All data were obtained from www.clinicaltrials.gov. McAb: monoclonal antibody, T‐Vec: talimogene laherparepvec.